Its unknown whether there are long-term implications for the AKI reported with GLP-1 receptor agonists
We recommended semaglutide treatment to be coupled with lifestyle interventions, and target dose of 20 mg or more subcutaneously once weekly
We track your progress monthly, monitor your health, and offer nutrition and fitness guidance
service as a consultant for AstraZeneca, Bayer Healthcare Pharmaceuticals, Biomea Fusion, Boehringer Ingelheim, Carmot, Eli Lilly, Intarcia, Intercept Pharmaceuticals, Janssen Global Services, Johnson & Johnson Medical Devices & Diagnostics GroupLatin America, MannKind Corporation, Merck, Novo Nordisk, Pfizer, Sanofi US Services, Shionogi, Structure Therapeutics, Target Pharma, Valeritas and Zealand Pharma A/S
These could be related to changes in diet, weight loss, or blood sugar levels